Roche's $425 million acquisition of geneWeave, an antibiotic diagnostics company

On August 13th Roche, which has returned to antibiotic drug development, signed another bill: the company spent $425 million on GeneWeave, an in-body diagnostics company, to strengthen its position in microbial diagnostics.
The two sides agreed that Roche would pay $190 million in advance to jointly develop a technology called "Fast Fire" that could be used to identify which antibiotics would be effective against terrain-positive, terrain-negative bacteria, help reduce mutations in bacterial resistance, and help patients make the right choices in the shortest possible time.
GeneWEAVE is privately owned and is based in California, USA. Not long ago, the company completed about $12 million in financing for Bren, and the investors will be included in Roche Diagnostics after the acquisition is completed.
Clermont Creek Ventures and XSeed Capital. It is understood that after the completion of the acquisition, the company will be included in Roche Diagnostics business unit, to retain the original staff.
Since 2015, Roche has invested in a strategy to return to antibiotic research and development: it has previously acquired Meiji Seika Pharmaceuticals and Fedora for $750 million to develop a β-endamidease inhibitor called OP0595, which is clinical in Phase I, and studies have shown that the drug's compound preparation with traditional antibiotics has effectively reduced e. coli bacterial resistance. Earlier, the company paid $560 million for Polyphor, and in 2014 it teamed up with Discuva, a British biotech company, to develop a range of new antibiotics.
addition to Roche, Mercadon paid $9.5 billion at the end of 2014 for the antiviral drug company Cubist Pharmaceuticals. (E-Drug Facebook)